NCT07166302 Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy
| NCT ID | NCT07166302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Masaryk University |
| Condition | Direct Acting Anticoagulant Adverse Reaction |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-09 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2025-09 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG. The aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.
Eligibility Criteria
Inclusion Criteria: * Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures * Willing and able to comply with all protocol procedures * subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing. * no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken. Exclusion Criteria: * Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject * other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.
Contact & Investigator
Eva Vlckova, MD
STUDY CHAIR
Masaryk University, University Hospital Brno
Frequently Asked Questions
Who can join the NCT07166302 clinical trial?
This trial is open to participants of all sexes, studying Direct Acting Anticoagulant Adverse Reaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07166302 currently recruiting?
Yes, NCT07166302 is actively recruiting participants. Contact the research team at betik.adam@fnbrno.cz for enrollment information.
Where is the NCT07166302 trial being conducted?
This trial is being conducted at Brno, Czechia, Brno, Czechia.
Who is sponsoring the NCT07166302 clinical trial?
NCT07166302 is sponsored by Masaryk University. The principal investigator is Eva Vlckova, MD at Masaryk University, University Hospital Brno. The trial plans to enroll 70 participants.